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Schistosomiasis is a prevalent neglected tropical disease that affects approximately 300 mil-
lion people worldwide. Its treatment is through a single class chemotherapy, praziquantel.
Concerns surrounding the emergence of praziquantel insensitivity have led to a need for
developing novel anthelmintics.
Methodology/Principle findings
Through evaluating and screening fourteen compounds (initially developed for anti-cancer
and anti-viral projects) against Schistosoma mansoni, one of three species responsible for
most cases of human schistosomiasis, a racemic N-acyl homoserine (1) demonstrated good
efficacy against all intra mammalian lifecycle stages including schistosomula (EC50 = 4.7 μM),
juvenile worms (EC50 = 4.3 μM) and adult worms (EC50 = 8.3 μM). To begin exploring struc-
tural activity relationships, a further 8 analogues of this compound were generated, including
individual (R)- and (S)- enantiomers. Upon anti-schistosomal screening of these analogues,
the (R)- enantiomer retained activity, whereas the (S)- lost activity. Furthermore, modification
of the lactone ring to a thiolactone ring (3) improved potency against schistosomula (EC50 =
2.1 μM), juvenile worms (EC50 = 0.5 μM) and adult worms (EC50 = 4.8 μM). As the effective
racemic parent compound is structurally similar to quorum sensing signaling peptides used by
bacteria, further evaluation of its effect (along with its stereoisomers and the thiolactone ana-
logues) against Gram+ (Staphylococcus aureus) and Gram- (Escherichia coli) species was
conducted. While some activity was observed against both Gram+ and Gram- bacteria spe-
cies for the racemic compound 1 (MIC 125 mg/L), the (R) stereoisomer had better activity
(125 mg/L) than the (S) (>125mg/L). However, the greatest antimicrobial activity (MIC 31.25
mg/L against S. aureus) was observed for the thiolactone containing analogue (3).
Conclusion/Significance
To the best of our knowledge, this is the first demonstration that N-Acyl homoserines exhibit
anthelmintic activities. Furthermore, their additional action on Gram+ bacteria opens a new
avenue for exploring these molecules more broadly as part of future anti-infective initiatives.
PLOS NEGLECTED TROPICAL DISEASES
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Author summary
Schistosomiasis, caused by infection with blood fluke schistosomes, is a neglected tropical
disease that negatively impacts the lives of approximately 300 million people worldwide.
In the absence of a vaccine, it is currently controlled by a single drug, Praziquantel (PZQ).
Although incredibly valuable in controlling disease burden, PZQ-mediated chemotherapy
is ineffective against juvenile worms and may not be sustainable should resistance develop.
The need to identify an alternative or combinatorial drug is, therefore, a priority in con-
tributing to the control of this parasitic disease into the 21st century. In this study, we have
identified a new class of anthelmintic, N-acyl homoserine lactones, which are normally
used by bacteria for quorum sensing and population density control. The tested N-acyl
homoserine lactones were active against all intra-human schistosome lifecycle stages, in
particular, when a thiolactone modification to the core N-acyl homoserine ring was made.
Interestingly, these N-acyl homoserine lactones also displayed antimicrobial activities
against Gram+ Staphylococcus aureus. By demonstrating broad activities against schisto-
somes and bacteria exemplars, this study identified a potential route for the further devel-
opment of a new anti-infective class.
Introduction
The development of drug resistant prokaryotic and eukaryotic pathogens is of great concern
for the sustainable control of both human and animal diseases; therefore, the need for new
anti-infectives is a global health priority. One notorious group of difficult to control pathogens
are those that cause the Neglected Tropical Diseases (NTDs). In total, 17 parasites/microbes
and their related infections are now identified as responsible for most NTDs worldwide [1],
with schistosomiasis, leishmaniasis and soil-transmitted helminthiasis causing significant dis-
ability adjusted life years lost per annum [2]. As vaccines are unavailable for the prevention of
most NTDs, a small number of chemotherapies remain the primary means of global control.
However, drug resistance or reduced susceptibility to these limited drug classes has been
reported for NTD-causing bacteria [3], fungi [4], helminths [5, 6] and protozoa [7, 8]. These
chemotherapy limitations have prompted an urgent need for research into the development of
new anti-infective agents. Nevertheless, funding to support this agenda is unlikely to originate
from the pharmaceutical sector due to the lack of financial returns associated with controlling
diseases predominantly affecting low to middle-income countries [9–11]. Thus, philanthropic
and public organisations are often driving the majority of new anti-infective initiatives target-
ing the NTDs with derived funding supporting research conducted in higher education or
research institutes.
One particular debilitating NTD, schistosomiasis, affects over 300 million people worldwide
[12] and is predominantly caused by infection with three Schistosoma species [13]. Therapeutic
treatment involves praziquantel (PZQ) as the frontline control strategy. However, PZQ is inef-
fective against the juvenile stage of the parasite in vivo, which necessitates repeat administra-
tions to reach maximal efficacy in endemic populations [14]. Furthermore, PZQ is currently
produced as a racemic mixture and only the (R)—enantiomer is active; the (S)—enantiomer
contributes to some of the side effects including bitter taste and non-compliance in the young
[15]. These drug-related limitations, together with a constant fear of PZQ resistance develop-
ing, has fuelled investigations into the identification of PZQ replacement or combinatorial
anti-schistosomal drugs.
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Towards this goal, our group has recently identified several diverse starting points for anti-
schistosomal drug discovery. These include diterpenoids [16, 17], triterpenoids [18], and epi-
genetic probes/inhibitors [19, 20]. While the primary focus of these investigations evaluated
compound-induced activity on Schistosoma mansoni (the schistosome species responsible for
both Old and New world schistosomiasis), parallel studies were also conducted to quantify
anti-infective activities against other NTD-causing pathogens including Fasciola hepatica
(liver fluke) [16–18] or NTD models such as Mycobacterium smegmatis (related toMycobacte-
rium leprae) [21].
In this present study, we assessed the anti-schistosomal activity of 14 in house prepared syn-
thetic compounds (or intermediate analogues of these compounds). As the most effective anti-
schistosomal compounds were structurally similar to N-acyl homoserines, a class of signalling
molecule involved in bacterial quorum sensing and population density control [22], we addi-
tionally investigated their anti-microbial activity. Amongst the compounds tested, one demon-
strated moderate activity against Gram+ (Staphylococcus aureus) bacteria. Our collective
results demonstrate that N-acyl homoserines represent a new class of anthelmintics with addi-
tional activity against bacteria. Further development of these molecules could be pursued as
promising new chemotherapeutics for schistosomiasis and other NTDs.
Materials and methods
Ethics statement
All procedures performed on mice (project licenses 40/3700 and P3B8C46FD) adhered to the
United Kingdom Home Office Animals (Scientific Procedures) Act of 1986 as well as the Euro-
pean Union Animals Directive 2010/63/EU and were approved by Aberystwyth University’s
(AU) Animal Welfare and Ethical Review Bodies (AWERB).
Synthetic methodology
Lactones (compounds 1–9) were prepared by the reaction of the lactone/thiolactone, with the
required acyl halide in the presence of NEt3 in chloroform or potassium carbonate in a two
phase water/chloroform mix (Scheme 1 in S1 Protocol). Yields and conditions are shown in
Table 1 and full synthetic and spectroscopic details are found in S1 Protocol.
Compound storage and handling
All compounds were solubilised in DMSO (Fisher Scientific, UK) to a stock concentration of
10 mM and stored at -20˚C until required. Positive controls for S. mansoni screens included
PZQ (Sigma-Aldrich, UK) and auranofin (Sigma-Aldrich, UK), which were also treated in the
same manner as the test compounds.
Screening of S. mansoni schistosomula
Biomphalaria glabrata (NMRI and the previously described pigmented strains [23]) snails
infected with S. mansoni (Puerto Rican strain) were shed for 2 hrs under light at 26 oC. Cercar-
iae were collected, mechanically transformed into schistosomula [24] and subsequently pre-
pared for high throughput screening (HTS) on the Roboworm platform as previously
described [17]. Schistosomula were cultured in Basch Media (composed of BME media, 10%
M169 media, 0.5x MEM vitamins, 10% Schneider’s insect media, 15.6mM Hepes, 5% heat
inactivated FBS, 2x Antibiotic/anti-mycotic (Sigma-Aldrich, UK) solution (final concentra-
tions shown)).
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Compounds were initially tested at a final concentration of 10 μM and those that were
active were further titrated at concentrations of 10, 5, 2.5, 1.25 and 0.625 μM. EC50 values were
calculated from the titrated concentrations by non-linear regression, after log transformation
of concentrations and data normalization using GraphPad Prism 7.02.
Screening of adult S. mansoni blood flukes (7-week worms)
Adult S.mansoni parasites were recovered by hepatic portal vein perfusion from TO outbred
mice (HsdOla:TO, Tuck-Ordinary, Envigo, UK) that were percutaneously infected seven
weeks earlier with 180 cercariae. Three adult worm pairs per well, in duplicate, were trans-
ferred into 48 well plates (Fisher Scientific, Loughborough, UK) and cultured at 37 oC in an
atmosphere containing 5% CO2 in DMEM (Gibco, Paisley, UK) containing 10% v/v HEPES,
10% v/v Foetal Bovine Serum (FBS), 0.7% v/v 200 mM L-Glutamine and 1X v/v penicillin-
streptomycin. Worms were dosed with test compounds at 20 μM, 10 μM, 5 μM, 2.5 μM,
1.25 μM and 0.625 μM (in 0.2% DMSO) for 72 hr. Adult worms were scored manually at 72 hr
using the WHO-TDR metric scoring system as described previously [25]. Dose response
curves and EC50 values were obtained by non-linear regression, after log transformation of
concentrations and data normalization using GraphPad Prism 7.02. At 72 hr, the medium
from each well was also collected, centrifuged at 350 x g for 2 min. Afterwards, the supernatant
was removed, and the remaining egg pellet re-suspended in 10% v/v formalin. Eggs that were
oval and contained a fully formed lateral spine were subsequently counted.
Screening of juvenile S. mansoni blood flukes (3-week worms)
Juvenile S.mansoni parasites were recovered via hepatic portal vein perfusion from TO out-
bred mice (HsdOla:TO, Tuck-Ordinary, Envigo, UK) that were infected percutaneously three
weeks earlier with 4000 cercariae. Preparation and centrifugation of juvenile worms have been
described previously [18]. Briefly, juvenile worms (n = 13–33 individuals/well) in 200 μl of a
96-well tissue culture plate were co-cultured with compounds (15 μM, 7.5 μM, 3.75 μM,
1.83 μM, 0.94 μM and 0.47 μM (in 1.25% DMSO) in DMEM (Gibco, Paisley, UK) supple-
mented with 10% v/v HEPES (Sigma-Aldrich, Gillingham, UK), 10% v/v FBS (Gibco, Paisley,
UK), 0.7% v/v 200 mM L-Glutamine (Gibco, Paisley, UK) and 1X v/v penicillin-streptomycin
Table 1. Preparatory summary of compounds 1–9.
Compound X Z R � # Method Yield Mp/˚C
1 Br O H Racemic NA A 75% 95–97
2 Br O Me Racemic Racemic A 33% 157–69
3 Br S H Racemic NA B 40% 111–3
4 Br S Me Racemic Racemic B 73% 125–28
5 Br O H R NA B 25% 130–3
6 Br O H S NA B 14% 130–3
7 Cl O H Racemic NA A 68% 111–5
8 Cl S H Racemic NA B 61% 124–7
9 Cl O Me Racemic Racemic A 65% 148–50
The symbols
“�” and
”#” refer to the absolute configuration at the carbon centres indicated in scheme 1.
NA = Not applicable
Z = O, S, R = H, Me.
https://doi.org/10.1371/journal.pntd.0008630.t001
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(Fisher Scientific, UK). Positive control wells included either PZQ or auranofin (15 μM in 1.25%
DMSO) whereas negative wells included DMSO (1.25%). Parasites were incubated at 37 oC in
an atmosphere containing 5% CO2 for 72 hr at which time worm motility was scored between 0
and 4: 0 = dead, 1 = movement of the suckers only and slight contraction of the body, 2 = move-
ment at the anterior and posterior regions only, 3 = full body movement but sluggish and
4 = normal movement. After motility quantification, 2 μg/mL of PI was added to each well and
the plate returned to 37˚C, 5% CO2 for 15 minutes [26]. Each well was subsequently imaged on
the Roboworm platform using brightfield and fluorescent microscopy (excitation wave-
length = 580 nm; emission wavelength = 604 nm). The number of PI positive vs PI negative
juvenile worms were cross-checked with the motility scores obtained by our scoring matrix, and
the data reported as percentage of PI positive across all parasites within the well. EC50 values
were calculated from the motility scores obtained from the dose response titration (as detailed
above) and dose response curves were obtained by non-linear regression, after log transforma-
tion of concentrations and data normalization using GraphPad Prism 7.02.
Cell cytotoxicity assays
The cytotoxicity of each compound was assessed on human HepG2 cells as described previ-
ously [17]. Briefly, 2 x 104 cells/well were seeded in black walled 96-well microtiter plates
(Fisher Scientific, Loughborough, UK) and incubated for 24 hr at 37˚C in a humidified atmo-
sphere containing 5% CO2. To each well, compounds were subsequently added to obtain final
concentrations (in 1% DMSO) of 100 μM, 75 μM, 50 μM, 25 μM, 10 μM and 5 μM. Following
a further incubation for 24 hr, the MTT assay was performed as previously described [17, 27].
Dose response curves were obtained by non-linear regression, after log transformation of con-
centrations and data normalization using GraphPad Prism 7.02.
Bacterial growth, minimum inhibitory concentration (MIC) calculation,
and EC50 determination
S. aureus ATCC 29213 and E. coli ATCC 25922 were cultured in Luria-Bertani (LB) medium
at 37˚C with aeration at 200 rpm for 24 hr, with all procedures performed in a biosafety level 2
(BSL2) cabinet. Stationary phase cultures were then used for minimum inhibitory concentra-
tion (MIC) determination using the broth microdilution method, in fresh LB medium, in a
96-well plate [28]. All compounds were tested in triplicate using an initial bacterial concentra-
tion of 5.0 × 105 colony forming units (CFU)/mL at a final concentration of 125 mg/L (5% and
2.5% v/v methanol). Compounds with no visible growth at 125 mg/L were further evaluated
with progressing dilutions. The MIC was determined as the lowest concentration of a
compound at which no growth was visible after 24 hr. Dilutions were repeated in three inde-
pendent experiments where the optical density (OD600) was measured in a Hidex plate spec-
trophotometer and absorbance data used for the calculation of an IC50 value. The IC50 value
was obtained from a dose response titration (125–0.09 mg/L). Dose response curves were
obtained by non-linear regression, after log transformation of concentrations and data nor-
malization using GraphPad Prism 7.02.
Bioinformatics
The names and structures (SMILES strings) of chemical compounds were identified in
PubMed abstracts in June 2019 using the chemistry text-mining software LeadMine v 3.1.2
(NextMove Software Ltd.) [29]. Chemical compounds were identified in all PubMed abstracts
containing any one of long list of words relating to schistosomes and anthelmintic/antipara-
sitic compounds (e.g. ’schistosoma’, ’sporocyst’, ’sporocysts’, ’miracidium’, ’miracidia’,
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’somule’, ’somules’, ’schistosomula’, ’schistosomulum’, ’cercariae’, ’cercaria’, ’schistosome’,
’schistosomes’, ’antiparasitic’, ’antinematodal’, ’anthelmintic’, etc.). The structures of our
screening hits were compared to those of the chemical compounds identified in PubMed
abstracts using DataWarrior [30], by using DataWarrior’s Similarity Analysis function with its
FragFP descriptor.
A map of the quorum sensing pathway in Pseudomonas aeruginosa was found using the
Kyoto Encyclopedia of Genes and Genomes (KEGG) database. Through this database, the
NCBI Protein IDs and the corresponding amino acid sequences were obtained for LasR
(NP_250121), LasI (NP_250123), RhIR (NP_252167), RHII (NP_252166). These sequences
were used as queries for a protein BLAST (BLASTp) search against the S.mansoni genome in
Wormbase-Parasite [31].
Statistics
All Statistical analyses were conducted using GraphPad Prism 7 software. To determine
significant differences amongst population means, a Kruskal-Wallis ANOVA followed by
Dunn’s multiple comparisons test was used. p values are indicated as follows: � <0.05, �� <0.01,
��� <0.001.
Results
As part of our anti-infective research activities, a total of 14 synthetic compounds (including
some intermediate analogues; S1 Table) were entered into a screening pipeline to identify
active molecules (Fig 1).
These 14 compounds (S1 Table) were initially screened against the larval stage of S.mansoni
(schistosomula) (S1 Fig). Amongst the collection, two compounds negatively affected both
schistosomula motility and phenotype metrics at 10 μM (Compound 1 and Compound E (S1A
Fig)). Subsequent titration of these two compounds demonstrated that Compound 1 was more
effective (an average EC50 of 4.7 μM for phenotype and motility) than Compound E (an aver-
age EC50 of 5.6 μM for phenotype and motility (S1B Fig)). Due to these initial anti-schistoso-
mula screens identifying compound 1 as being moderately potent, a total of 8 analogues, all
containing a lactone ring core structure but differing in functional group modifications, were
synthesised to further assess anti-schistosomal activities (S1 Table).
Firstly, in a direct comparison to compound 1, each of the 8 analogues as well as compound
1 were titrated against the schistosomula stage to assess compound-induced changes to para-
site motility and/or phenotype (Fig 2).
Out of the nine compounds titrated, four affected schistosomula motility (44.4%; com-
pounds 1, 3, 4 and 5) (Fig 2A). Compounds 4 and 5 affected the motility of the parasites at
both 10 and 5 μM, whereas compound 1 and 3 affected the motility at all concentrations tested.
When evaluating compound-mediated alterations of schistosomula phenotypes, five of the
nine compounds had an effect (55.6%; compounds 1, 3, 4, 5 and 7) (Fig 2B). Analogues 4, 5
and 7 affected the phenotype of the parasites at 10 and 5 μM, compound 1 affected this metric
from 10 to 1.25 μM and compound 3 affected the phenotype of the schistosomula at all con-
centrations tested. Therefore, a substitution of the simple lactone ring (1) for a thiolactone
ring (3) increased comparative anti-schistosomula potency at all concentrations tested. Of par-
ticular interest is the comparison of the two enantiomeric forms of Compound 1. The (R)-
enantiomer (5) affected schistosomula for both phenotype and motility at 10 μM and 5 μM
concentrations. However, no anti-schistosomula activity was observed for the (S)-enantiomer
(6), suggesting that stereo-specificity of N-acyl homoserine is critical to structural activity rela-
tionships (SAR).
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Fig 1. The screening pipeline utilised in this anti-infective study. A total of 14 compounds were initially screened against S.mansoni
schistosomula at a final concentration of 10 μM. Hits were subsequently subjected to dose response titrations with the most effective anti-
schistosomula compound (Compound 1) subsequently being used as a template for the preparation of further derivatives (compounds
2–9). Compounds 2–9 were subsequently subjected to dose response titrations against schistosomula and adult worms. The most
PLOS NEGLECTED TROPICAL DISEASES N-Acyl homoserine lactones as anti-schistosomals
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Due to initial indications that these analogues had varying activities against the schistoso-
mula lifecycle stage (Table 2), the parent compound and its 8 analogues (Compounds 1–9)
were subsequently screened against 7-week old adult male and female worms (Fig 3).
Initially, these screens were conducted at 20 μM; any compounds that scored a 1 or 0 for
motility at this primary concentration were further titrated until no further effect was
observed. For Compound 1, an EC50 for males was estimated to be 8.2 μM and for females
8.3 μM (Fig 3A). Similar to the schistosomula assays, the differences observed in adult parasite
motility when treated with the (R)- and (S)- enantiomers of Compound 1 were striking. The
(R)-enantiomer (5) caused complete immobility at the highest dose of 20 μM; conversely, the
(S)-enantiomer (6) did not have this effect. Estimated EC50s for male and female parasites for
these two enantiomers were determined (Table 2), with Compound 5 ((R)- enantiomer) hav-
ing greater activity than Compound 6 ((S)- enantiomer).
While the propanamide analogue (2) had no activity against the adults, the thiolactone ana-
logue (3) had good activity (similar to its effects on schistosomula) with significant reduction
in motility observed down to 5 μM; EC50s of 4.2 μM for males and 3.9 μM for females were
determined (Table 2). The thiolactone propanamide analogue (4) only demonstrated lethality
at the highest concentration of 20 μM with an EC50 of 10.5 μM and 18.4 μM for males and
females respectively (Table 2). No lethality/motility defects were observed for any of the
chloro- analogues (Compounds 7, 8 and 9).
As morbidity associated with schistosomiasis is caused by egg-induced granuloma forma-
tion in tissues and the subsequent development of fibrotic lesions around these granulomas
[32], compound-mediated modulation of in vitro egg production (as a surrogate for the in vivo
pathology initiator) was next assessed (Fig 3B). Specifically, media derived from adult worm
cultures incubated with compounds that resulted in complete immobility/lethality (com-
pounds 1, 3, 4, and 5; compound 6 was also included as the (S)- stereoisomer of compound 1)
were collected and eggs counted (Fig 3B). In comparison to the negative control DMSO, in
which egg counts ranged from 300–594 (Average—408), all N-Acyl homoserine lactones
affected fecundity. The parent Compound (1) significantly affected egg laying down to 10 μM
(p< 0.0022) when compared to DMSO. While both (R)-(compound 5) and (S)- (compound
6) enantiomers reduced egg production, the (R)- enantiomer was more effective. Of the com-
pounds evaluated, Compound 3 was, once again, the most potent. Here, fecundity was signifi-
cantly reduced at concentrations down to 2.5 μM (p = 0.0413) when compared to DMSO
controls. While egg production was still affected at 1.25 μM, this was not statistically significant
(p> 0.9999).
Next, we further evaluated the most potent analogue (compound 3) on 3-week old juvenile
worms and compared its effect to that induced by the racemic parent compound (1) (Fig 4).
For compound 1, an EC50 of 4.3μM was noted with significant effect on worm motility
down to 7.5 μM (p =<0.0001) (Fig 4A). For the thiolactone analogue (3), complete immobility
was observed down to 0.94 μM (p<0.0001 for all concentrations) and an EC50 of 0.5 μM deter-
mined (Fig 4B). This data is consistent with the findings observed in schistosomula and the
7-week adult worm screens where incorporation of a thiolactone resulted in more effective
anti-schistosomal activity. To additionally demonstrate that these N-Acyl homoserine lactones
led to juvenile worm death, propidium iodide was utilised in compound 1 and 3 co-cultures
(Fig 5).
effective compounds (original compound 1 and analogue 3) were next titrated against juvenile worms. Finally, compounds 1, 3, 5 and 6
were additionally titrated against both Gram+ (S. aureus) and Gram- (E. coli) bacterial exemplars.
https://doi.org/10.1371/journal.pntd.0008630.g001
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The number of PI positive parasites when dosed with compound 1 was 100% at 15 and
7.5 μM concentrations, 13.3% at 3.75 μM and 0% for all other concentrations (Fig 5A). In con-
trast, co-culture in compound 3 resulted in 100% of the parasites being PI positive down to
0.94 μM (Fig 5B); this result tightly aligns to the motility scores quantified by light microscopy
(Fig 4). Therefore, compounds 1 and 3 are not simply immobilising the juvenile parasites but
are, in fact, killing them. To note, control juvenile parasites were also assessed for PI uptake
(Fig 5C). For DMSO treated parasites, as expected with high motility scores, 0% of the para-
sites scored PI positive. Interestingly, PZQ treated parasites also displayed similar results to
that of DMSO treated parasites where 0% of the juvenile worms were PI positive. This is in
contradiction to PZQ-treated parasites scoring the lowest (0–1) for motility (Fig 4) and illus-
trates that, while this drug decreases motility, it does not kill juvenile stage parasites. Aurano-
fin-treated parasites were all (100%) PI positive.
Evaluation of the indicative cytotoxic effect of these compounds against HepG2 cells was
subsequently tested. Compounds 1–6 were titrated (from 200–1 μM) on HepG2 cells and co-
cultivated for 24 hrs. A previous large scale mammalian cytotoxicity study indicated that maxi-
mal HepG2 cytotoxicity was observed within the first 24 hrs for 91% of the effective
Fig 2. Anti-schistosomula activity of the eight analogues compared to parent compound 1. A total of 120
mechanically transformed schistosomula were co-cultured with each compound, titrated at doses between 10 and
0.625 μM. Test plates were incubated at 37˚C for 72 hrs in an atmosphere containing 5% CO2. At 72hrs, schistosomula
were scored using the Roboworm platform for both motility (A) and phenotype (B). Any compound that induced a
score of below -0.35 for motility (A) and -0.15 for phenotype (B) were considered a hit. Black squares indicate the most
positive effect on motility or phenotype; grey scale from dark grey to lighter shades of grey indicates a progressive
reduced compound efficacy; white squares indicate no effect on either phenotype or motility. Z´ values for this screen
was 0.41741 for motility and 0.57275 for phenotype. (C) Phenotypes of schistosomula when treated with 10μM of each
of the test compounds and controls.
https://doi.org/10.1371/journal.pntd.0008630.g002
Table 2. Calculated EC50, CC50 and subsequent selectivity indices of N-acyl homoserines.
COMPOUND ID SCHISTOSOMULA EC50 ADULT WORM EC50 JUVENILE WORM EC50 HepG2 CC50
Phenotype Motility Male Female
1 5.6 CI (4.9–6.2) 3.8 CI (2.4–5.2) 8.2 CI (7.0–9.4) 8.3 CI �� 4.3 CI �� 43.5 CI (29.1–57.9)
2 >10 CI � >10 CI � >20 CI � >20 CI � >200
3 2.3 CI (1.7–3.1) 1.9 CI (1.3–2.9) 4.2 CI (3.9–4.6) 3.9 CI (3.4–4.5) 0.5 CI �� 18.7 CI (14.2–23.2)
4 4.9 CI (4.5–5.2) 4.6 CI (4.1–5.0) >10 CI �� >10 CI �� 70.8 CI (57–84.8)
5 4.0 CI �� 3.1 CI �� >10 CI �� >10 CI �� 50.6 CI (40.8–60.4)
6 >10 CI � >10 CI � 16.0 CI (13.5–20.1) >20 CI � >100 CI�
SELECTIVITY INDICES
1 7.9 11.5 5.3 5.2 10.1
2




Average EC50 calculated for each compound and life cycle stage of the parasite. Values are expressed as μM concentrations and 95% confidence intervals are shown. For
compound 4 and 5, adult male EC50 is stated as >10 μM due to a rapid recovery in motility observed between 20 μM and 10 μM and, therefore, a more accurate estimate
could not be obtained without further titration points between 20μM and 10μM.
� Confidence intervals (CI) were not calculated due to no compound effect seen at the highest dose tested
�� Confidence intervals (CI) not calculable due to the motility scores obtained at the tested concentrations being too narrow (WHO-TDR scores of 3 and 4 only or 0 and
4 only), and therefore an accurate 95% CI could not be calculated.
https://doi.org/10.1371/journal.pntd.0008630.t002
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Fig 3. Adult schistosome motility and egg production are differentially affected by the nine N-acyl homoserine lactones. A) Adult S.
mansoni worm pairs were cultured in decreasing compound concentrations of between 20 μM and 1.25 μM (not all concentrations were
used for all compounds) for 72 hrs at 37˚C, 5% CO2. Parasite motility was evaluated for each sex and scored using the WHO-TDR scoring
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compounds [33]; therefore, 24 hrs continuous co-incubation of N-acyl homoserine lactones
with HepG2 cells was selected for this study. The racemic compound (1) had an EC50 of
43.5 μM (Table 2) on HepG2 cells. Evaluation of the individual enantiomers demonstrated
that (R)- and (S)- enantiomers had higher EC50 concentrations compared to the parent com-
pound 1 (50.6 μM and>100 μM respectively). Incorporation of the thiolactone (3) resulted in
greater cytotoxicity (EC50 = 18.7μM) with a 2.3 fold increase in comparison to compound 1.
With the EC50 data collected for schistosomula, adult and juvenile worms as well as the
CC50 for HepG2, the selectivity indices (SI) could be determined for each of the compounds
tested (Table 2). For all lifecycle stages tested, the thiolactone analogue (3) had the lowest EC50
values; however, it also had the poorest CC50 values of all the compounds tested, which
resulted in some of the lowest SI scores except for juvenile worms where a SI of 37.4 was
noted.
Due to limited information regarding potential targets of compound 1, we next conducted
an evaluation of structural similarities to previously published compounds as a first step
towards this goal (Fig 6).
Using LeadMine and Datawarrior tools [30], compound 1 was found to be structurally sim-
ilar to that of the N-butanoyl-l-homoserine lactones C4-HSL and PAI-2 (Fig 6A). Within P.
aeruginosa, the N-3-oxo-dodecanoyl-l-homoserine lactone C12 and C4 signal through LasR
and RhIR to facilitate quorum sensing [35] (Fig 6B). In addition to this function, both C4 and
C12 HSLs regulate gene expression within P. aeruginosa as well as within several mammalian
host cells [36–38]. Subsequently, we evaluated whether compound 1 may target similar S.man-
soni orthologues to those used by P. aeruginosa in facilitating C4-HSL and C12-HSL signal
transduction events. Upon BLATSP analyses of the S. mansoni genome, our findings failed to
provide convincing evidence for LasR, LasI, RhIR, RHII (P. aeruginosa) orthologues. This sug-
gests that our N-acyl homoserine analogue (1) is operating through differing mechanisms to
that seen within bacteria, as has been postulated for mammalian systems [37, 38].
As Compound 1 was structurally similar to N-acylhomoserine lactones, a compound class
involved in bacterial quorum sensing, we decided to assess its antimicrobial activity and deter-
mine if enantiomer separation or lactone ring substitution would change this activity. Com-
pounds 1, 3, 5 and 6 were thus screened against representative Gram+ (Staphylococcus aureus)
and Gram- (Escherichia coli) species at final concentrations of 125, 62.5, 31.25, 15.6, 7.8 and 3.9
mg/L. Minimum inhibitory concentrations (MIC) were determined and represent the mini-
mum concentration associated with no visible bacterial growth. The racemic compound (1)
showed a MIC of 125 mg/L for both bacteria species, which was a similar value to that obtained
for the (R)-enantiomer (5). In contrast, the (S)-enantiomer (6) did not show any activity
(> 125 mg/L) on either bacterial species indicating that, similarly to the anthelmintic activity,
the (R)-enantiomer alone is responsible for the antimicrobial activity (Table 3). When the lac-
tone ring was replaced with a thiolactone substituent (3), the activity was considerably
improved leading to a MIC of 31.25 mg/L for S. aureus (IC50 = 25.9 mg/L) and 62.5 mg/L for
E. coli (IC50 = 52.7 mg/L) (Table 3).
Discussion
The drive to identify new anti-infectives is of paramount importance due to the continuous
documentation and threat of drug resistant pathogens [39–42]. In particular, our research
system (0 = Dead parasite, 4 = Normal/Healthy movement). B) Culture media were collected from some adult co-cultures at 72 hrs and
eggs present in the media were counted. p values are indicated as follows: � <0.05, �� <0.01, ��� <0.001.
https://doi.org/10.1371/journal.pntd.0008630.g003
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Fig 4. Three week juvenile worms are immobilised by N-Acyl homoserine lactones. Three-week old juvenile S.
mansoni worms (n = 13–33 per well) were co-cultured with compounds (1) and (3) at concentrations spanning 15 μM
—0.23 μM for 72 hrs at 37˚C in a humidified atmosphere containing 5% CO2. Parasite motility was scored between
0–4 (0 = no movement/dead, 4 = full movement/healthy). DMSO negative controls were also included (1.25% final
concentration) as well as two positive controls (15 μM PZQ and 15 μM auranofin; both in 1.25% DMSO). A) Effect of
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group has focused on identifying new chemotherapeutic compounds effective against S.man-
soni, one of three major species responsible for human schistosomiasis.
In this study, 14 compounds were initially screened against schistosome parasites. It was
evident that compound (1) had good activity against a range of lifecycle stages (schistosomula,
adult and juvenile worms); therefore, a further 8 analogues (including the separated enantio-
mers) were generated. Interestingly the (R)-enantiomer was more effective when compared to
the (S)-enantiomer in all of the parasitic assays conducted in this study; the (R)-enantiomer
alone was also less toxic than parent compound 1 (EC50 50.6μM and 43.5μM respectively). It is
not surprising that different activities are associated with enantiomers; indeed PZQ itself is
only effective via its (R)- enantiomer [43]. For example, Patterson et al demonstrated that the
(R)-enantiomer of PA-824 (a promising antitubercular drug) had greater activity (when com-
pared to the (S) enantiomer) against L. donovani during in vivo studies [44]. Furthermore, Par-
edes et al demonstrated that (R)-albendazole sulfoxide had greater anthelmintic activity
against T. solium when compared to (S)-albendazole [45]. Our data, along with these and
other parasitic studies [46], provides clear evidence that compound chirality represents an
important consideration for drug discovery progression and putative target identification.
Upon further exploration of structural activity relationships, we found that elongation of
the N-acyl chain led to decreased activity (1 vs 2; 3 vs 4), while substitution of the lactone ring
with a thiolactone improved activity (1 vs 3, 2 vs 4) and led to the most effective compound 3.
It is reasonable to speculate that should 3 be available as the pure (R)-enantiomer, improve-
ments in both anti-schistosomal potency and host cell cytotoxicity would be found (similar to
those observed for compound 1 versus enantiomer pure (R) - 5 and (S) - 6). A reduction in
schistosome fecundity was noted in cultures co-incubated with 3 vs 4; therefore, it could be
argued that the addition of the methyl group in position 2 to the thiolactone analogue reduces
parasite fecundity.
Comparative structural analysis revealed that compound 1, having been previously charac-
terised as an intermediary product of one-step procedures for producing Gram- N-acyl homo-
serines [47, 48], was similar to that of quorum sensing N-acyl homoserines. In recent years,
quorum sensing has become a focus of development as a target for new anti-infective treat-
ments [49]. Quorum sensing is a method by which both eukaryotic and prokaryotic cells regu-
late gene expression in response to fluctuations in cell population densities. Of relevance to
parasites, Trypanosoma brucei is known to regulate its surrounding population by an analo-
gous quorum sensing mechanism. In order to evade the host immunity response, trypano-
somes adopt a slender morphology to proliferate, and in order to enter their transmission
stage will transform into a stumpy form in which they stop proliferating [50]. This differentia-
tion between two morphologically and molecular lifecycle stages is dependent on parasite den-
sity, and therefore can be seen as a type of quorum sensing [51, 52]. Much work has gone into
identifying the mechanisms responsible for this density sensing to provide potential quorum
sensing drug targets in trypanosomes [52]. Quorum sensing in schistosomes (or other meta-
zoan endoparasites), to regulate lifecycle transitions, has not yet been identified.
With the identification of our parent compound having structural similarities to that of
quorum-sensing N-acyl homoserines, we decided to evaluate compounds 1 and 3 (the most
effective compound against S. mansoni), as well as the (R)- and (S)- enantiomers (5 and 6
respectively) against both Gram+ and Gram- bacteria to assess their potential as antimicrobials.
Our findings in the bacteria screens were consistent with the S. mansoni data in that 3 was the
compound (1) on juvenile worm motility. (B) Effect of compound (3) on juvenile worm motility. p values are
indicated as follows: � <0.05, �� <0.01, ��� <0.001.
https://doi.org/10.1371/journal.pntd.0008630.g004
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Fig 5. N-Acyl homoserine lactones kill juvenile stage schistosomes. Three week juvenile schistosomes, incubated
with compounds (1), (3) or controls for 72 hrs, were subsequently cultured with PI at a final concentration of 2 μg/mL
for 15 minutes at 37 oC in an environment containing 5% CO2. PI positive parasites (dead) were counted and the
percent live vs dead in each well is indicated. A) Quantification of compound (1) mediated juvenile death. B)
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most potent, although only moderately active in comparison to clinical standards [53], N-acyl
homoserine against Gram+ bacteria and that the (R)- (5) was more effective than the (S)- (6)
enantiomer. Furthermore, the thiolactone (3) had a 4- and 2- fold improvement in activity
against S. aureus and E. coli respectively, compared to compound 1. It is interesting that N-
acyl homoserines should have greater effect against a Gram+ bacteria, which in natural envi-
ronments do not utilise these compounds as part of their quorum sensing regulation [54]. An
explanation for increased inhibition of S. aureus growth when treated with compound 3 may
be due to cross-inhibition between bacteria species. It has previously been demonstrated that
bacteria undergo strategies to reduce the efficacy of quorum sensing used by competitor bacte-
rial species and thus increase the likelihood of their own survival [54, 55]. The role of N-acyl
homoserines in this process of cell to cell bacterial communication has been clearly demon-
strated for S. aureus and P. aeruginosa [56]. Here, N-acyl homoserines (e.g. 3-oxo-C12-HSL)
produced by Gram- P. aeruginosa inhibit growth and virulence factor production of Gram+
S. aureus. When co-inhabiting infected tissues, this N-acyl homoserine-mediated strategy of
cell communication provides P. aeruginosa with a competitive advantage over S. aureus. Other
studies have also demonstrated a role for N-acyl homoserines in mediating pathogen popula-
tion densities; for example, Candida albicans filamentation can be suppressed by 3-oxo-C12-
HSL (homoserine lactone) produced by P. aeruginosa [57]. It is, therefore, likely that our syn-
thetic N-acyl homoserine analogues (especially thiolactone containing compound 3) inhibit S.
aureus growth in a similar manner as the above examples or those additional ones found in the
literature illustrate (54, 55). For example, McInnis et al have previously designed and validated
a library of 21 thiolactone analogues that were either naturally occurring or non-native N-acyl
homoserines and evaluated their effect as agonists and antagonists of LuxR-type quorum sens-
ing receptors in P.aeruginosa (LasR), V. fischeri (LuxR), and A.tumefaciens (TraR). They were
able to demonstrate the improved potency of the thiolactone analogues in comparison to the
N-acyl homoserine parent compound (similar to our findings here) [58].
In P. aeruginosa, its N-acyl homoserines primarily function through the transcription factors
LasR and RhIR, but similar orthologues were not identified in the S.mansoni genome. How-
ever, it has also been shown that bacterial N-acyl homoserines mediate cross-Kingdom commu-
nication by directly interacting with membrane lipids; this mechanism of action may be
responsible for the anti-schistosomal effects observed in our studies. For example, long chain
N-acyl homoserines (e.g. 3-oxo-C12-HSL) can insert into cholesterol-containing microdomains
leading to changes in dipole potential, integral protein re-organisation and subsequent activa-
tion of signal transduction cascades [36, 59]. The intra-mammalian schistosome is covered by
two tightly opposed lipid bilayers including an inner plasma membrane and an outer membra-
nocalyx [60–62]. The membranocalyx has the highest density of intramembranous particles
[63] comprised of nutrient transporters, transmembrane proteins and other gene products of
currently unknown function [64–66]. Also, it is rich in neutral lipids, cholesterol and phospho-
lipids [67–70]. It is possible that the compounds analysed in this study may bind to the choles-
terol rich regions within this membranocalyx layer, which subsequently causes conformational
changes to the transmembrane proteins affecting their downstream signalling cascades. This
could ultimately result in the phenotypes observed in our studies. However, as compounds dis-
playing greater lipophilicity did not necessarily increase anthelmintic activity, features such as
chemical space/composition and size may be more important. Further experimentation is
required to tease apart the mode of action of these anthelmintic compounds.
Quantification of compound (3) mediated juvenile death. C) Quantification of juvenile deaths in co-cultures
containing 15 μM PZQ (in 1.25% DMSO), 15 μM auranofin (in 1.25% DMSO) and 1.25% DMSO.
https://doi.org/10.1371/journal.pntd.0008630.g005
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To the best of our knowledge, this is the first study to demonstrate that synthetic bacterial
N-acyl homoserines analogues are effective against S. mansoni. This is a new avenue of investi-
gation as these compounds represent novel starting points for future anthelmintic drug discov-
ery studies. We have also demonstrated the importance of enantiomer contribution, in line
with previous findings, and that some molecules display cross-pathogen activity. When taken
together, these findings could inform the development of new, broad-acting anti-infectives.
Supporting information
S1 Protocol. Detailed materials and methods for chemical synthesis of compounds 1–9.
(DOCX)
S1 Table. Structural details of all compounds screened against S. mansoni in this study.
The first 14 compounds represent the initial compounds screened. The following 8 are com-
pound 1 analogues.
(XLSX)
S1 Fig. Initial schistosomula screens of the 14 compounds and their intermediate ana-
logues. A total of 120 mechanically transformed schistosomula were co-cultured with each
compound, titrated at doses between 10 and 0.625 μM. Test plates were incubated at 37˚C for
72 hrs in an atmosphere containing 5% CO2. At 72hrs, schistosomula were scored using the
Roboworm platform for both motility and phenotype as previously described [17, 25]. A) Of
the 14 compounds evaluated, two fell within the hit region. Z’ scores for motility and pheno-
type were 0.40079 and 0.56846 respectively. B) Further titration of the two hit compounds
resulted in good compound effect being observed for compound 1 down to a concentration of
1.25 μM. Z´ scores for motility and phenotype were 0.37864 and 0.47882 respectively.
�Average EC50 value across motility and phenotype is presented for each compound.
(TIF)
Fig 6. In silico approach to identify potential targets of compound 1 within S. mansoni. A) FragFP output in DataWarrior demonstrates that Compound 1
is structurally related to C4-HSL (formerly called PAI-2 [34]); C4-HSL is an N-acyl homoserines involved in quorum sensing within P. aeruginosa. Substitution
of the methyl and bromine groups (found in compound 1) is observed with propyl and stereochemistry modifications. B) Pathways in P. aeruginosa that utilise
both C4- and C12- HSLs (LasI = acyl-homoserine-lactone synthase; LasR = transcriptional activator; RhlR = regulatory protein RhlI = acyl-homoserine-lactone
synthase). Highlighted (red rectangles) are those P. aeruginosa proteins used in BLASTp analysis of the S.mansoni genome (v 7.0).
https://doi.org/10.1371/journal.pntd.0008630.g006
Table 3. Antibacterial activity (MIC) of the tested compounds and antibacterial selectivity of compound 3 (IC50).
Compound ID S. aureus E. coli S. aureus E. coli CC50 (μM)
(HepG2)
Selectivity Index
























Minimum inhibitory concentration of compounds expressed as mg/L [μM] against Staphylococcus aureus and Escherichia coli. IC50 against S. aureus and E. coli
determined from three independent experiments and expressed as mg/L [μM] with 95% confidence interval (in parentheses). Selectivity indices were calculated from
HepG2 CC50 values.
https://doi.org/10.1371/journal.pntd.0008630.t003
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